Glucagon-like peptide 1 (GLP-1) and eating.
New information regarding gastrointestinal mechanisms that participate in the control of food intake has extended our understanding of appetite control. Although each new signaling pathway discovered in the gut is a potential target for drug development in the treatment of obesity, the growing number of such signaling molecules indicates that a highly complex process controls food intake. The present summary focuses on the role of glucagon-like peptide 1 (GLP-1) in this regulatory process. The different biological effects of GLP-1 (glucose-lowering properties, inhibition of appetite and food intake) provide a powerful impetus for development of GLP-1-based new drugs.
Gutzwiller
Jean-Pierre
JP
Division of Gastroenterology, University Hospital, Basel, Switzerland.
Degen
Lukas
L
Heuss
Ludwig
L
Beglinger
Christoph
C
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D004064:Digestive System; D004435:Eating / Q000502:physiology*; D005934:Glucagon / Q000819:agonists / Q000276:immunology / Q000502:physiology*; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D010446:Peptide Fragments / Q000819:agonists / Q000276:immunology / Q000502:physiology*; D011498:Protein Precursors / Q000819:agonists / Q000276:immunology / Q000502:physiology*; D018027:Receptors, Glucagon / Q000502:physiology
D000906:Antibodies; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D010446:Peptide Fragments; D011498:Protein Precursors; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1; D005934:Glucagon